Trial Profile
BELOVA: a Non-Interventional Study to Collect Data on the Safety and Efficacy of Frontline Bevacizumab Treatment in Ovarian Cancer Patients 70 Years and Older.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jun 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Acronyms BELOVA; BGOG-ov16
- Sponsors Roche
- 06 Jun 2022 Results published in the International Journal of Gynecological Cancer
- 23 Jul 2019 Status changed from active, no longer recruiting to completed.
- 31 May 2018 Planned End Date changed from 1 Aug 2019 to 30 Jul 2019.